Compare SLDB & BHRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLDB | BHRB |
|---|---|---|
| Founded | 2013 | 1852 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 968.8M |
| IPO Year | 2017 | 2023 |
| Metric | SLDB | BHRB |
|---|---|---|
| Price | $9.29 | $71.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 5 |
| Target Price | $16.36 | ★ $71.80 |
| AVG Volume (30 Days) | ★ 893.5K | 106.8K |
| Earning Date | 05-12-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 3.46% |
| EPS Growth | 34.97 | ★ 173.76 |
| EPS | N/A | ★ 2.16 |
| Revenue | ★ $8,094,000.00 | N/A |
| Revenue This Year | N/A | $36.62 |
| Revenue Next Year | N/A | $10.06 |
| P/E Ratio | ★ N/A | $32.87 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.79 | $57.42 |
| 52 Week High | $11.45 | $75.09 |
| Indicator | SLDB | BHRB |
|---|---|---|
| Relative Strength Index (RSI) | 56.37 | 45.47 |
| Support Level | $6.25 | $68.38 |
| Resistance Level | $11.45 | $73.55 |
| Average True Range (ATR) | 0.45 | 1.40 |
| MACD | 0.09 | -0.47 |
| Stochastic Oscillator | 66.77 | 25.71 |
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
Burke & Herbert Financial Services Corp is the bank holding company. Through its subsidiary, it predominantly serves small to medium-sized businesses, their owners and employees, professional corporations, non-profits, and individuals with various banking products and financial services. Some of its products and service offerings include checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential mortgage, acquisition, construction, and development loans, online banking, mobile banking, and wealth and trust services. The company operates in a single segment, namely Community Banking.